How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

On Jul 17, J&J (JNJ) announced strong second-quarter results, beating estimates for both earnings and sales. While the Innovative Medicines segment outperformed expectations, MedTech's performance was a bit softer than expected due to macroeconomic issues in China, increased competitive pressure and currency headwinds.Sales of J&J’s Innovative Medicines segment rose 5.5% year over year. Higher sales of key products such as Darzalex, Stelara, Tremfya, Uptravi and Erleada drove the segment’s growth. New drugs ...